No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
doxorubicin hydrochloride
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
ifosfamide + epirubicin + mesna
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
AIM
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
entrectinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
GT
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
ifosfamide
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
larotrectinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
gemcitabine + dacarbazine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
cediranib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
sunitinib
Sensitive: A2 - Guideline
|
ALK translocation
ALK translocation
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
crizotinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
regorafenib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
temozolomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
dacarbazine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
gemcitabine + vinorelbine tartrate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
gemcitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
MAID
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
epirubicin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
entrectinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
eribulin mesylate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
gemcitabine + docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
ifosfamide + doxorubicin hydrochloride + mesna
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
AD
Sensitive: A2 - Guideline
|
ALK translocation
ALK translocation
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
brigatinib
Sensitive: A2 - Guideline
|
ALK translocation
ALK translocation
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
ceritinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
bevacizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
sorafenib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
vinorelbine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
SA033
Sensitive: A2 - Guideline
|
MSH3 overexpression
MSH3 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
ifosfamide + epirubicin
Resistant: B - Late Trials
|
No biomarker
No biomarker
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
liposomal annamycin
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
nivolumab + ipilimumab
Sensitive: C1 - Off-label
|
KIAA1549-BRAF fusion
KIAA1549-BRAF fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
bevacizumab + sorafenib + temsirolimus
Sensitive: C3 – Early Trials
|
CUL4A overexpression
CUL4A overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
trabectedin
Sensitive: C3 – Early Trials
|
ERCC5 overexpression
ERCC5 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
trabectedin
Sensitive: C3 – Early Trials
|
ERCC1 overexpression
ERCC1 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
trabectedin
Sensitive: C3 – Early Trials
|
TAF15-NR4A3 fusion
TAF15-NR4A3 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
sunitinib
Resistant: C3 – Early Trials
|
EWSR1-NR4A3 fusion
EWSR1-NR4A3 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
sunitinib
Sensitive: C3 – Early Trials
|
SMARCB1 deletion
SMARCB1 deletion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
tazemetostat
Sensitive: C3 – Early Trials
|
SS18-SSX fusion
SS18-SSX fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
venetoclax + S63845
Sensitive: C3 – Early Trials
|
IFIH1 expression
IFIH1 expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
Immunotherapy
Sensitive: C3 – Early Trials
|
CTSG expression
CTSG expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
Immunotherapy
Sensitive: C3 – Early Trials
|
STC2 expression
STC2 expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
Immunotherapy
Sensitive: C3 – Early Trials
|
SECTM1 expression
SECTM1 expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
Immunotherapy
Sensitive: C3 – Early Trials
|
LAG3 overexpression
LAG3 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
trabectedin
Sensitive: C3 – Early Trials
|
CTLA4 overexpression
CTLA4 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
trabectedin
Sensitive: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
trabectedin
Sensitive: C3 – Early Trials
|
CDK4 amplification
CDK4 amplification
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
palbociclib
Sensitive: C3 – Early Trials
|
RB1 expression
RB1 expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
palbociclib
Sensitive: C3 – Early Trials
|
TFE3 rearrangement + MET expression
TFE3 rearrangement + MET expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
crizotinib
Sensitive: C3 – Early Trials
|
HMGA1 overexpression
HMGA1 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
trabectedin
Resistant: C3 – Early Trials
|
HDAC1 amplification
HDAC1 amplification
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
PD1 inhibitor + chidamide
Sensitive: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
pazopanib
Resistant: C3 – Early Trials
|
CLDN6 positive
CLDN6 positive
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
|
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib
Sensitive: C3 – Early Trials
|
MAD2L2 underexpression
MAD2L2 underexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib + trabectedin
Sensitive: C3 – Early Trials
|
XRCC2 underexpression
XRCC2 underexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib + trabectedin
Sensitive: C3 – Early Trials
|
RAD54L underexpression
RAD54L underexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib + trabectedin
Sensitive: C3 – Early Trials
|
BLM underexpression
BLM underexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib + trabectedin
Sensitive: C3 – Early Trials
|
APEX2 underexpression
APEX2 underexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib + trabectedin
Sensitive: C3 – Early Trials
|
ATM overexpression
ATM overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib + trabectedin
Sensitive: C3 – Early Trials
|
SLFN11 overexpression
SLFN11 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib + trabectedin
Sensitive: C3 – Early Trials
|
PIK3R1 overexpression
PIK3R1 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib + trabectedin
Sensitive: C3 – Early Trials
|
CDKN2A overexpression
CDKN2A overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
olaparib + trabectedin
Sensitive: C3 – Early Trials
|
LMNA-NTRK1 fusion
LMNA-NTRK1 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
RANBP2-ALK fusion
RANBP2-ALK fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
doxorubicin hydrochloride
Resistant: C4 – Case Studies
|
RANBP2-ALK fusion
RANBP2-ALK fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
crizotinib
Sensitive: C4 – Case Studies
|
ATF1 overexpression
ATF1 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
ruxolitinib
Sensitive: C4 – Case Studies
|
PDE4DIP-NTRK1 fusion
PDE4DIP-NTRK1 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
ifosfamide + doxorubicin hydrochloride
Resistant: C4 – Case Studies
|
YWHAE-ROS1 fusion
YWHAE-ROS1 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
crizotinib
Sensitive: C4 – Case Studies
|
PDE4DIP-NTRK1 fusion
PDE4DIP-NTRK1 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
JAK1 overexpression
JAK1 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
ruxolitinib
Sensitive: C4 – Case Studies
|
PIK3CA E542K
PIK3CA E542K
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
trametinib + pazopanib
Sensitive: C4 – Case Studies
|
DCTN1-NTRK1 fusion
DCTN1-NTRK1 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
BAY 2731954
Resistant: C4 – Case Studies
|
DCTN1-NTRK1 fusion
DCTN1-NTRK1 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
larotrectinib
Resistant: C4 – Case Studies
|
STRN-NTRK2 fusion + CDKN2B Deletion
STRN-NTRK2 fusion + CDKN2B Deletion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
PD-L1 expression
PD-L1 expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
camrelizumab
Sensitive: C4 – Case Studies
|
IGF1R expression
IGF1R expression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
IGF-1R inhibitor
Sensitive: D – Preclinical
|
RAD23B overexpression
RAD23B overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
vorinostat
Sensitive: D – Preclinical
|
CSPG4 overexpression
CSPG4 overexpression
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
CSPG4.TNK
Sensitive: D – Preclinical
|
EWSR1-WT1 fusion
EWSR1-WT1 fusion
|
Soft Tissue Sarcoma
Soft Tissue Sarcoma
|
trabectedin
Sensitive: D – Preclinical
|
